Home›Drug Pipeline› Systematic review of pharmacist-led interventions in hematological malignancies
Systematic review of pharmacist-led interventions in hematological malignanciesPharmacists Help Blood Cancer Patients Avoid Dangerous Drug Risks
Frontiers in MedicinePublished April 24, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider pharmacist-led interventions may improve medication processes in hematological malignancies, but clinical outcomes are heterogeneous.
This is a systematic review of 33 studies on pharmacist-led interventions for patients with hematological malignancies in inpatient and outpatient settings. The authors synthesized evidence on medication management processes, adherence, toxicity management, patient-reported outcomes, disease response, survival, hospitalization, and economic outcomes.
The review found that medication management processes were most consistently improved. Identification and resolution of drug-related problems, drug interaction management, care coordination, and acceptance of pharmacist recommendations were also improved. Improvements in medication adherence and toxicity management were reported in several studies, and selected improvements in patient-reported outcomes were noted.
However, findings for disease response, survival, and hospitalization were heterogeneous and not consistently statistically significant. Economic evaluations were limited, though they suggested potential cost savings and favorable returns on investment.
The authors acknowledged substantial heterogeneity in study design, interventions, and outcome definitions, and noted that evidence for effects on clinical and economic outcomes remains limited and heterogeneous. Practice relevance is restrained to improvements in medication management processes and potential contributions to adherence and safety.
Why Safety Is The Top Priority
Doctors work hard to prescribe the right mix. But the list of medicines gets long. It is easy for mistakes to happen. A drug might clash with another. Or the dose might be too high.
How The Care Team Is Changing
Traditionally, doctors handled all the prescriptions. They focused on killing the cancer. But they did not always check every single interaction. Now, pharmacists are joining the team. They specialize in how drugs work in the body.
The Pharmacist As A Safety Shield
Think of a pharmacist like a security guard for your medicine. They scan every drug you take. They look for hidden dangers. They make sure the timing is right.
Researchers looked at 33 different studies. These studies covered both hospital and clinic settings. They focused on patients with blood cancers. The goal was to see if pharmacists made a difference.
The Key Results Explained
The results were clear on safety. Pharmacists found and fixed many drug problems. They stopped potential interactions before they happened. Patients also took their medicines more often.
But there is a catch regarding survival rates.
What Doctors Say About It
Experts say this is a step forward. It shows that specialized care matters. But we need more data on long-term health. Some studies showed cost savings too.
How You Can Use This Info
You should ask if a pharmacist is on your team. It is not a magic cure. It is a safety net. Talk to your doctor about adding this support.
Why The Results Are Mixed
The studies were not all the same. Some were small. Some looked at different things. This makes it hard to compare results directly.
What Happens Next In Research
More research is needed. We need to know if this saves lives. Future studies will focus on standardizing how we measure success.
BackgroundPharmacist-led interventions are increasingly integrated into hematology-oncology care to address complex pharmacotherapy and medication safety challenges. However, their impact within hematological malignancies has not been comprehensively synthesized across clinical, process-related, and economic domains.MethodsA systematic review was conducted to evaluate pharmacist-led interventions in patients with hematological malignancies across inpatient and outpatient settings. Thirty-three studies were included. Owing to substantial heterogeneity in study design, interventions, and outcome definitions, a structured qualitative synthesis was performed, with findings grouped by clinical, process-related, and economic outcomes.ResultsThirty-three studies were included, reporting clinical (n = 24), process-related (n = 23), and economic outcomes (n = 8). Pharmacist-led interventions most consistently improved medication management processes, including identification and resolution of drug-related problems, drug interaction management, and care coordination, with high acceptance rates of pharmacist recommendations. Several studies also reported improvements in medication adherence, toxicity management, and selected patient-reported outcomes; however, findings for disease response, survival, and hospitalization were heterogeneous and not consistently statistically significant. Economic evaluations were limited but suggested potential cost savings and favorable returns on investment associated with pharmacist involvement.ConclusionPharmacist-led interventions in hematology-oncology care improve medication management processes and may contribute to better adherence and medication safety. However, evidence for effects on clinical and economic outcomes remains limited and heterogeneous, highlighting the need for well-designed prospective studies using standardized outcome measures.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251147239, identifier CRD420251147239.
